Literature DB >> 6641100

Influence of oxidation polymorphism on phenformin kinetics and dynamics.

N S Oates, R R Shah, J R Idle, R L Smith.   

Abstract

Plasma and urinary kinetics and responses of blood lactate, pyruvate, and glucose after a single 50-mg phenformin dose were investigated in eight subjects of known debrisoquin oxidation phenotype, four poor metabolizers (PM) and four extensive metabolizers (EM). Higher peak plasma concentrations of phenformin (152.2 +/- 12.7 ng/ml; mean +/- SE) and a greater plasma AUC (779 +/- 99 ng X hr X ml-1) were reached in PM than in EM (99.8 +/- 13.7 ng/ml and 549 +/- 47 ng X hr X ml-1). Although the urinary excretion of unchanged phenformin was greater in PM between 2 and 24 hr after dosing than in EM, excretion of 4-hydroxy-phenformin could not be detected in most samples collected from PM but was present in every sample from EM. Blood lactate concentrations increased dramatically in PM but fell in EM after phenformin. There were no changes in either blood pyruvate or glucose levels. The results may help to explain lactic acidosis in patients given phenformin in the absence of other predisposing factors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6641100     DOI: 10.1038/clpt.1983.257

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Clinical pharmacology physiology conference: metformin and lactic acidosis (LA).

Authors:  Chadi Alkhalil; George Zavros; Fadi Bailony; David T Lowenthal
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 2.  Inborn 'errors' of drug metabolism. Pharmacokinetic and clinical implications.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

3.  Genetic polymorphisms, drug metabolism and drug concentrations.

Authors:  Gillian M Shenfield
Journal:  Clin Biochem Rev       Date:  2004

4.  Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin.

Authors:  M S Lennard; J C McGourty; J H Silas
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

5.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine.

Authors:  D M Pierce; S E Smith; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  The genetic control of phenformin 4-hydroxylation.

Authors:  R R Shah; D A Evans; N S Oates; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1985-10       Impact factor: 6.318

Review 8.  Still sour about lactic acidosis years later: role of metformin in heart failure.

Authors:  William Kuan; Craig J Beavers; Maya E Guglin
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

9.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  The effects of diabetes mellitus, exercise, and single doses of biguanides upon lactate metabolism in man.

Authors:  P Fletcher; M R Hirji; S Kuhn; L Alexander; J C Mucklow
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.